A Phase 3 trial of the lung cancer drug Tagrisso (osimertinib) will be unblinded early on the recommendation of the data monitoring committee on evidence of overwhelming efficacy, the developer AstraZeneca Plc announced on 10 April. Tagrisso, a tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR), has already been approved for first and second-line use in patients with advanced non-small lung cancer. The Phase 3 trial, called ADAURA, was treating patients with early-stage disease. The primary endpoint of the trial is disease-free survival.
